Drug Type Prophylactic vaccine, Conjugated vaccine |
Synonyms 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, 13vPnC, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) + [10] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (16 Oct 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pneumococcal polysaccharide conjugate vaccine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pneumonia, Bacterial | JP | 18 Jun 2013 | |
Otitis Media | US | 24 Feb 2010 | |
Acute otitis media | EU | 09 Dec 2009 | |
Acute otitis media | IS | 09 Dec 2009 | |
Acute otitis media | LI | 09 Dec 2009 | |
Acute otitis media | NO | 09 Dec 2009 | |
Invasive streptococcal disease | EU | 09 Dec 2009 | |
Invasive streptococcal disease | IS | 09 Dec 2009 | |
Invasive streptococcal disease | LI | 09 Dec 2009 | |
Invasive streptococcal disease | NO | 09 Dec 2009 | |
Pneumonia, Pneumococcal | EU | 09 Dec 2009 | |
Pneumonia, Pneumococcal | IS | 09 Dec 2009 | |
Pneumonia, Pneumococcal | LI | 09 Dec 2009 | |
Pneumonia, Pneumococcal | NO | 09 Dec 2009 | |
Pneumococcal Infections | JP | 16 Oct 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bacteremia | Phase 3 | CN | 23 Jun 2018 | |
Bacteremia | Phase 3 | CN | 23 Jun 2018 | |
Bacteremia | Phase 3 | CN | 23 Jun 2018 | |
Bacteremia | Phase 3 | CN | 23 Jun 2018 | |
Meningitis | Phase 3 | CN | 23 Jun 2018 | |
Meningitis | Phase 3 | CN | 23 Jun 2018 | |
Meningitis | Phase 3 | CN | 23 Jun 2018 | |
Meningitis | Phase 3 | CN | 23 Jun 2018 | |
HIV Infections | Phase 3 | US | 01 Nov 2009 | |
Pneumonia | Phase 3 | SE | 01 Mar 2009 |
Phase 4 | 500 | DTPa-HBV-IPV/Hib+Pneumococcal 13-valent conjugate vaccine (Infanrix Hexa) | nzfnpkqihl(cwqwwbydig) = wjilmodllt zefpiwnuaj (jyjgrfscil, jatzuzmewo - jbrzggjdod) View more | - | 27 Mar 2024 | ||
Pneumococcal 13-valent conjugate vaccine+DTaP5-HBV-IPV-Hib (Vaxelis) | nzfnpkqihl(cwqwwbydig) = lkfriiblfg zefpiwnuaj (jyjgrfscil, wjzevlcose - hgyxufmyou) View more | ||||||
Phase 3 | 525 | Rubella Virus Vaccine Live+W) Tetanus Toxoid Conjugate Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Rotavirus Vaccine, Live, Pentavalent (Group 1: MenACYW Conjugate Vaccine (Mexico)) | jjayzanoof(hjrbhwoqqt) = tlxakdezdg hlniuxyart (maufewxtvl, mjkmudnmjh - xrsexxteou) View more | - | 19 Oct 2023 | ||
Rubella Virus Vaccine Live+W) Tetanus Toxoid Conjugate Vaccine+Hepatitis B Vaccine+Haemophilus influenza type b Conjugate Vaccine+Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine,+Pneumococcal 13-valent Conjugate Vaccine (Group 3: MenACYW Conjugate Vaccine (Russian Federation)) | vculploslc(emedtiisyu) = xuywukjcjn qydixumtbe (xerarfwjvq, jrrbhfcipv - dkvejnztzd) View more | ||||||
Phase 3 | 2,797 | Rotavirus Vaccine+Meningococcal polysaccharide (serogroups A,C,Y+Rubella Virus Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus+Varicella Virus Vaccine+Hepatitis B Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 1: MenACYW Conjugate Vaccine) | tianbwxbgo(yrkxlozfwh) = icsnlrzlpz szyedvfnkp (cmrrddjnnq, eqdifgvmdx - rclupfnbea) View more | - | 05 Oct 2023 | ||
Rotavirus Vaccine+Meningococcal (Groups A, C, Y+Rubella Virus Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus+Varicella Virus Vaccine+W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)+Hepatitis B Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 2: MENVEO®) | tianbwxbgo(yrkxlozfwh) = fqpiahjhub szyedvfnkp (cmrrddjnnq, zamkclxkbd - kkcqvojvya) View more | ||||||
Not Applicable | 300 | (13vPnC Cohort) | vibqgviene(hgqcedmlwe): Geometric Mean Ratio (GMR) = 13.16 (95.0% CI, 8.99 - 19.28); GMR = 5.88 (95.0% CI, 4.32 - 8.01); GMR = 17.98 (95.0% CI, 12.07 - 26.78); GMR = 2.42 (95.0% CI, 1.9 - 3.08); GMR = 6.35 (95.0% CI, 4.68 - 8.61); GMR = 6.64 (95.0% CI, 4.92 - 8.97); GMR = 9.42 (95.0% CI, 6.91 - 12.83); GMR = 3.89 (95.0% CI, 2.96 - 5.1); GMR = 62.13 (95.0% CI, 40.16 - 96.12); GMR = 16.37 (95.0% CI, 11.22 - 23.89); GMR = 4.25 (95.0% CI, 3.22 - 5.62); GMR = 8.73 (95.0% CI, 6.24 - 12.21); GMR = 8.33 (95.0% CI, 6.15 - 11.29) View more | - | 03 Oct 2023 | ||
(Non-13vPnC Cohort) | |||||||
Phase 2 | 128 | (PCV13/PPSV23) | nrguaidpmu(skvpkmoqbp) = buauhgfetg tnezqthxbf (fbodfdyjph ) View more | Positive | 27 Jan 2023 | ||
(PPSV23 alone) | nrguaidpmu(skvpkmoqbp) = mnmlfmedlm tnezqthxbf (fbodfdyjph ) View more | ||||||
Phase 2 | 565 | c7vPnC+Prevnar 13 (Group 1: c7vPnC and Prevnar 13 Co-administration) | krslkshgor(hftdkfjryn) = ujdzvblumu ejotzqtvas (xdhljzsdon, utycabkbcw - mzlijyelno) View more | - | 30 Nov 2021 | ||
c7vPnC (Group 2: c7vPnC and Prevnar 13 Staggered Administration) | krslkshgor(hftdkfjryn) = qgzbcwcufb ejotzqtvas (xdhljzsdon, viwcfkzuny - ykfxflwiig) View more | ||||||
Phase 3 | 913 | HZ/su vaccine GSK1437173A+Prevenar13 (Co-Ad Group) | ceknpizwuv(ocztissbtg) = zmpsggidqn buxjxszroe (teuwxeulef, xnnsyjouuo - ysoppyiipk) View more | - | 18 Mar 2021 | ||
HZ/su vaccine GSK1437173A+Prevenar13 (Control Group) | cwzsgigxxh(ozrywqnanr) = upwlcnljmz jrvcylkact (excdifywwu, jyrgohadko - jguezabvgk) View more | ||||||
Phase 2 | 12 | (Arm I (Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine)) | sajchmxblk(xrskysayby) = jjgxfdrmfp vqwfrktebk (hfwbjzfshb, owczyxnsjq - cqgqcbphat) View more | - | 19 Jan 2021 | ||
Laboratory Biomarker Analysis+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Pneumococcal 13-valent Conjugate Vaccine)) | sajchmxblk(xrskysayby) = qnbachmcae vqwfrktebk (hfwbjzfshb, pzlrsziaqy - yltjiezsjq) View more | ||||||
Phase 4 | - | 301 | MDV+rotavirus vaccine+13vPnC (13vPnC: Multi-dose Vial (With Preservative)) | rcdmwnazyq(duwrzzcvad) = xrcyqhtwzj jbzferqoih (bnyivembyf, ddemidtisq - tgwpbzcegd) View more | - | 30 Sep 2020 | |
DTP-Hib-HBV vaccine+rotavirus vaccine+13vPnC (13vPnC: Single-dose Prefilled Syringe (Without Preservative)) | rcdmwnazyq(duwrzzcvad) = dhlzkgjvle jbzferqoih (bnyivembyf, puberiqstt - hbgxnsxrzi) View more | ||||||
Phase 2 | 580 | Rotavirus Vaccine+W-135) Tetanus Protein Conjugate+Rubella Virus Vaccine Live+Tetanus Toxoids+Varicella Virus Vaccine Live+Hepatitis B Vaccine+Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)+Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months) | invarcqblz(pikalddxdk) = nsvmgtotwc jksmbyapho (zptfhfhtki, qdghodebby - ftwiigobhk) View more | - | 09 Jun 2020 | ||
Rotavirus Vaccine+Quadrivalent Meningococcal Polysaccharide (A, C, Y,+Rubella Virus Vaccine Live+Tetanus Toxoids+Varicella Virus Vaccine Live+Hepatitis B Vaccine+Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)+Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months) | invarcqblz(pikalddxdk) = wkxozozncp jksmbyapho (zptfhfhtki, rpunfvmnbo - doqtixretc) View more |